Company intelligence / Profile preview

Shanghai Zeke Biotechnology Co., Ltd.

Shanghai, Shanghai Shi, Chinazerunbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company's only known clinical program, CT101a for relapsed/refractory AML, entered a Phase 1 dose escalation study to evaluate safety and preliminary efficacy. The trial was terminated/discontinued before completion. No positive clinical results have been reported.

Therapeutic areas: Oncology
Modalities: Cell therapyImmunotherapyImmunologic cytotoxicityGene-modified cell therapy
Industry: Biotech

Drug pipeline

1 asset

CT101A

Partnerships

Zhejiang University

Beyond the preview

Go deeper on Shanghai Zeke Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Zeke Biotechnology Co., Ltd..